Your browser doesn't support javascript.
[Progress in the study of antiviral activity of cepharanthine against SARS-CoV-2].
Fan, H; Liu, K; Hong, B; He, S; Han, P; Li, M; Wang, S; Tong, Y.
  • Fan H; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
  • Liu K; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
  • Hong B; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
  • He S; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
  • Han P; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
  • Li M; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
  • Wang S; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
  • Tong Y; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Nan Fang Yi Ke Da Xue Xue Bao ; 42(6): 955-956, 2022 Jun 20.
Article in Chinese | MEDLINE | ID: covidwho-1924684
ABSTRACT
As a member of the dibenzyl isoquinoline alkaloid family, cepharathine is an alkaloid from the traditional Chinese medicine cepharathine, which is mainly used for treatment of leukopenia and other diseases. Recent studies of the inhibitory effect of cepharathine against SARS-CoV-2 have attracted widespread attention and aroused heated discussion. As the original discoverer of the anti-SARS-CoV-2 activity of cepharanthine, here we briefly summarize the discovery of cepharanthine and review important progress in relevant studies concerning the discovery and validation of anti-SARS-CoV-2 activity of cepharathine, its antiviral mechanisms and clinical trials of its applications in COVID-19 therapy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Benzylisoquinolines / COVID-19 Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: Chinese Journal: Nan Fang Yi Ke Da Xue Xue Bao Year: 2022 Document Type: Article Affiliation country: J.issn.1673-4254.2022.06.22

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Benzylisoquinolines / COVID-19 Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: Chinese Journal: Nan Fang Yi Ke Da Xue Xue Bao Year: 2022 Document Type: Article Affiliation country: J.issn.1673-4254.2022.06.22